Astrocytes in amyotrophic lateral sclerosis: Harmful effects and strategies to afford neuroprotection

New Developments in Astrocytes Research

Volumn , Issue , 2016, Pages 75-116

  Vaz, A R ^a,b   Gomes, C ^b   Cunha, C ^b   Brites, D ^a,b  

^a Department of Biochemistry and Human Biology ^*  (United Kingdom)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85019646950     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (187)

1. Kumar DR, Aslinia F, Yale SH, Mazza JJ. Jean-Martin Charcot: the father of neurology. Clin Med Res. 2011;9(1): 46-9.
2. Turner MR, Brockington A, Scaber J, Hollinger H, Marsden R, Shaw PJ, et al., Pattern of spread and prognosis in lower limb-onset ALS. Amyotroph Lateral Scler. 2010;11(4): 369-73.
3. Kuhnlein P, Gdynia HJ, Sperfeld AD, Lindner-Pfleghar B, Ludolph AC, Prosiegel M, et al., Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol. 2008;4(7): 366-74.
4. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4: 3.
5. Chen S, Sayana P, Zhang X, Le W. Genetics of amyotrophic lateral sclerosis: an update. Molecular neurodegeneration. 2013;8(1): 28.
6. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, et al., Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185(2): 232-40.
7. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006;7(9): 710-23.
8. Bendotti C, Carri MT. Lessons from models of SOD1-linked familial ALS. Trends in molecular medicine. 2004;10(8): 393-400.
9. Redler RL, Dokholyan NV. The complex molecular biology of amyotrophic lateral sclerosis (ALS). Prog Mol Biol Transl Sci. 2012;107: 215-62.
10. Proctor EA, Fee L, Tao Y, Redler RL, Fay JM, Zhang Y, et al., Nonnative SOD1 trimer is toxic to motor neurons in a model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2016;113(3): 614-9.
11. Shefner JM, Reaume AG, Flood DG, Scott RW, Kowall NW, Ferrante RJ, et al., Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy. Neurology. 1999;53(6): 1239-46.
12. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al., Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264(5166): 1772-5.
13. Gruzman A, Wood WL, Alpert E, Prasad MD, Miller RG, Rothstein JD, et al., Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2007;104(30): 12524-9.
14. Ezzi SA, Urushitani M, Julien JP. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem. 2007;102(1): 170-8.
15. Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, et al., Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci. 2010;13(11): 1396-403.
16. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11): 616-30.
17. Baldwin KR, Godena VK, Hewitt VL, Whitworth AJ. Axonal transport defects are a common phenotype in Drosophila models of ALS. Hum Mol Genet. 2016.
18. Costa J, de Carvalho M. Emerging molecular biomarker targets for amyotrophic lateral sclerosis. Clin Chim Acta. 2016;455: 7-14.
19. Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, et al., Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87(1): 12-20.
20. Menke RA, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A, et al., CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol. 2015;2(7): 748-55.
21. Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al., Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22): 2247-57.
22. Song S, Miranda CJ, Braun L, Meyer K, Frakes AE, Ferraiuolo L, et al., Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis. Nat Med. 2016;22(4): 397-403.
23. Re DB, Le Verche V, Yu C, Amoroso MW, Politi KA, Phani S, et al., Necroptosis Drives Motor Neuron Death in Models of Both Sporadic and Familial ALS. Neuron. 2014;81(5): 1001-8.
24. Bilican B, Serio A, Barmada SJ, Nishimura AL, Sullivan GJ, Carrasco M, et al., Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A. 2012;109(15): 5803-8.
25. Meyer K, Ferraiuolo L, Miranda CJ, Likhite S, McElroy S, Renusch S, et al., Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc Natl Acad Sci U S A. 2014;111(2): 829-32.
26. Boillée S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52(1): 39-59.
27. Pramatarova A, Laganiere J, Roussel J, Brisebois K, Rouleau GA. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci. 2001;21(10): 3369-74.
28. Gong YH, Parsadanian AS, Andreeva A, Snider WD, Elliott JL. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J Neurosci. 2000;20(2): 660-5.
29. Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al., Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312(5778): 1389-92.
30. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al., Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11(3): 251-3.
31. Grad LI, Yerbury JJ, Turner BJ, Guest WC, Pokrishevsky E, O'Neill MA, et al., Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and-independent mechanisms. Proc Natl Acad Sci U S A. 2014;111(9): 3620-5.
32. Vardjan N, Zorec R. Excitable Astrocytes: Ca(2+)-and cAMPRegulated Exocytosis. Neurochem Res. 2015;40(12): 2414-24.
33. Verkhratsky A, Matteoli M, Parpura V, Mothet JP, Zorec R. Astrocytes as secretory cells of the central nervous system: idiosyncrasies of vesicular secretion. EMBO J. 2016;35(3): 239-57.
34. Pekny M, Pekna M, Messing A, Steinhauser C, Lee JM, Parpura V, et al., Astrocytes: a central element in neurological diseases. Acta Neuropathol. 2016;131(3): 323-45.
35. Choi DS, Kim DK, Kim YK, Gho YS. Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. Proteomics. 2013;13(10-11): 1554-71.
36. Brites D, Fernandes A. Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation. Front Cell Neurosci. 2015;9: 476.
37. Díaz-Amarilla P, Olivera-Bravo S, Trias E, Cragnolini A, Martinez-Palma L, Cassina P, et al., Phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2011;108(44): 18126-31.
38. Basso M, Pozzi S, Tortarolo M, Fiordaliso F, Bisighini C, Pasetto L, et al., Mutant copper-zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis. J Biol Chem. 2013;288(22): 15699-711.
39. Ludolph AC, Jesse S. Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials. Ther Adv Neurol Disord. 2009;2(5): 319-26.
40. Chung WS, Barres BA. The role of glial cells in synapse elimination. Curr Opin Neurobiol. 2012;22(3): 438-45.
41. Allaman I, Belanger M, Magistretti PJ. Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci. 2011;34(2): 76-87.
42. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1): 7-35.
43. Simon NG, Turner MR, Vucic S, Al-Chalabi A, Shefner J, Lomen-Hoerth C, et al., Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol. 2014;76(5): 643-57.
44. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7(11): 603-15.
45. Rakhit R, Crow JP, Lepock JR, Kondejewski LH, Cashman NR, Chakrabartty A. Monomeric Cu, Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J Biol Chem. 2004;279(15): 15499-504.
46. McCombe PA, Henderson RD. The Role of immune and inflammatory mechanisms in ALS. Curr Mol Med. 2011;11(3): 246-54.
47. Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10(3): 253-63.
48. Saleh IA, Zesiewicz T, Xie Y, Sullivan KL, Miller AM, Kuzmin-Nichols N, et al., Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression. J Neuroimmunol. 2009;215(1-2): 96-101.
49. Migheli A, Cordera S, Bendotti C, Atzori C, Piva R, Schiffer D. S-100beta protein is upregulated in astrocytes and motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis. Neurosci Lett. 1999;261(1-2): 25-8.
50. Süssmuth SD, Sperfeld AD, Hinz A, Brettschneider J, Endruhn S, Ludolph AC, et al., CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology. 2010;74(12): 982-7.
51. Süssmuth SD, Tumani H, Ecker D, Ludolph AC. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett. 2003;353(1): 57-60.
52. Hoyaux D, Boom A, Van den Bosch L, Belot N, Martin JJ, Heizmann CW, et al., S100A6 overexpression within astrocytes associated with impaired axons from both ALS mouse model and human patients. J Neuropathol Exp Neurol. 2002;61(8): 736-44.
53. Kaplan A, Spiller KJ, Towne C, Kanning KC, Choe GT, Geber A, et al., Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration. Neuron. 2014;81(2): 333-48.
54. Vaz AR, Cunha C, Gomes C, Schmucki N, Barbosa M, Brites D. Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration. Mol Neurobiol. 2015;51(3): 864-77.
55. Demestre M, Parkin-Smith G, Petzold A, Pullen AH. The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J Neuroimmunol. 2005;159(1-2): 146-54.
56. Patin F, Corcia P, Madji Hounoum B, Veyrat-Durebex C, Respaud E, Piver E, et al., Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis. Eur J Neurol. 2015; 22(10): 1385-90.
57. Shibata N, Hirano A, Hedley-Whyte ET, Dal Canto MC, Nagai R, Uchida K, et al., Selective formation of certain advanced glycation end products in spinal cord astrocytes of humans and mice with superoxide dismutase-1 mutation. Acta Neuropathol. 2002;104(2): 171-8.
58. Ilzecka J. Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2009;120(2): 119-22.
59. Boison D, Aronica E. Comorbidities in Neurology: Is adenosine the common link? Neuropharmacology. 2015;97: 18-34.
60. Almad AA, Doreswamy A, Gross SK, Richard JP, Huo Y, Haughey N, et al., Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis. Glia. 2016.
61. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblath DR, Drachman DB, et al., Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol. 1990;28(1): 18-25.
62. Texido L, Hernandez S, Martin-Satue M, Povedano M, Casanovas A, Esquerda J, et al., Sera from amyotrophic lateral sclerosis patients induce the non-canonical activation of NMDA receptors "in vitro." Neurochem Int. 2011;59(6): 954-64.
63. Amara SG, Fontana AC. Excitatory amino acid transporters: keeping up with glutamate. Neurochem Int. 2002;41(5): 313-8.
64. Bristol LA, Rothstein JD. Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann Neurol. 1996;39(5): 676-9.
65. Howland DS, Liu J, She Y, Goad B, Maragakis NJ, Kim B, et al., Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A. 2002;99(3): 1604-9.
66. Barbeito LH, Pehar M, Cassina P, Vargas MR, Peluffo H, Viera L, et al., A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev. 2004;47(1-3): 263-74.
67. Guo Y, Duan W, Li Z, Huang J, Yin Y, Zhang K, et al., Decreased GLT-1 and increased SOD1 and HO-1 expression in astrocytes contribute to lumbar spinal cord vulnerability of SOD1-G93A transgenic mice. FEBS Lett. 2010;584(8): 1615-22.
68. Rao SD, Yin HZ, Weiss JH. Disruption of glial glutamate transport by reactive oxygen species produced in motor neurons. J Neurosci. 2003;23(7): 2627-33.
69. Li K, Hala TJ, Seetharam S, Poulsen DJ, Wright MC, Lepore AC. GLT1 overexpression in SOD1(G93A) mouse cervical spinal cord does not preserve diaphragm function or extend disease. Neurobiol Dis. 2015;78: 12-23.
70. Van Damme P, Bogaert E, Dewil M, Hersmus N, Kiraly D, Scheveneels W, et al., Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci U S A. 2007;104(37): 14825-30.
71. Almer G, Vukosavic S, Romero N, Przedborski S. Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem. 1999;72(6): 2415-25.
72. Sasaki S, Warita H, Abe K, Iwata M. Inducible nitric oxide synthase (iNOS) and nitrotyrosine immunoreactivity in the spinal cords of transgenic mice with a G93A mutant SOD1 gene. J Neuropathol Exp Neurol. 2001;60(9): 839-46.
73. Cassina P, Cassina A, Pehar M, Castellanos R, Gandelman M, de Leon A, et al., Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrialtargeted antioxidants. J Neurosci. 2008;28(16): 4115-22.
74. Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, et al., Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011;29(9): 824-8.
75. Endo F, Komine O, Fujimori-Tonou N, Katsuno M, Jin S, Watanabe S, et al., Astrocyte-derived TGF-beta1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep. 2015;11(4): 592-604.
76. Hensley K, Abdel-Moaty H, Hunter J, Mhatre M, Mou S, Nguyen K, et al., Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J Neuroinflammation. 2006;3: 2.
77. Hensley K, Mhatre M, Mou S, Pye QN, Stewart C, West M, et al., On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal. 2006;8(11-12): 2075-87.
78. Johann S, Heitzer M, Kanagaratnam M, Goswami A, Rizo T, Weis J, et al., NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia. 2015;63(12): 2260-73.
79. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7): 677-87.
80. Tomankova T, Petrek M, Gallo J, Kriegova E. MicroRNAs: Emerging Regulators of Immune-Mediated Diseases. Scand J Immunol. 2011;75(2): 129-41.
81. 8Kye MJ, Goncalves Ido C. The role of miRNA in motor neuron disease. Front Cell Neurosci. 2014;8: 15.
82. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9): 597-610.
83. Parisi C, Arisi I, D'Ambrosi N, Storti AE, Brandi R, D'Onofrio M, et al., Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell Death Dis. 2013;4: e959.
84. Volonté C, Apolloni S, Parisi C. MicroRNAs: newcomers into the ALS picture. CNS Neurol Disord Drug Targets. 2015;14(2): 194-207.
85. Figueroa-Romero C, Hur J, Lunn JS, Paez-Colasante X, Bender DE, Yung R, et al., Expression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms. Mol Cell Neurosci. 2015;71: 34-45.
86. Koval ED, Shaner C, Zhang P, du Maine X, Fischer K, Tay J, et al., Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet. 2013;22(20): 4127-35.
87. Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, et al., Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol. 2014;77(1): 75-99.
88. Magna M, Pisetsky DS. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol Med. 2014;20: 138-46.
89. Smith TW, Tyler HR, Schoene WC. Atypical astrocytes and Rosenthal fibers in a case of amyotrophic lateral sclerosis associated with a cerebral glioblastoma multiforme. Acta Neuropathol. 1975;31(1): 29-34.
90. Kamo H, Haebara H, Akiguchi I, Kameyama M, Kimura H, McGeer PL. A distinctive distribution of reactive astroglia in the precentral cortex in amyotrophic lateral sclerosis. Acta Neuropathol. 1987;74(1): 33-8.
91. Nagy D, Kato T, Kushner PD. Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J Neurosci Res. 1994;38(3): 336-47.
92. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, et al., Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10(5): 615-22.
93. Lepore AC, Rauck B, Dejea C, Pardo AC, Rao MS, Rothstein JD, et al., Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci. 2008;11(11): 1294-301.
94. Kondo T, Funayama M, Tsukita K, Hotta A, Yasuda A, Nori S, et al., Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Reports. 2014;3(2): 242-9.
95. Lepore AC, O'Donnell J, Kim AS, Williams T, Tuteja A, Rao MS, et al., Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. PLoS One. 2011;6(10): e25968.
96. Brites D, Vaz AR. Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Front Cell Neurosci. 2014;8: 117.
97. Khakh BS, Sofroniew MV. Diversity of astrocyte functions and phenotypes in neural circuits. Nat Neurosci. 2015;18(7): 942-52.
98. Tarassishin L, Suh HS, Lee SC. LPS and IL-1 differentially activate mouse and human astrocytes: role of CD14. Glia. 2014;62(6): 999-1013.
99. Nicaise C, Mitrecic D, Falnikar A, Lepore AC. Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury. World J Stem Cells. 2015;7(2): 380-98.
100. Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cellbased ALS model. Nat Neurosci. 2007;10(5): 608-14.
101. Di Giorgio FP, Boulting GL, Bobrowicz S, Eggan KC. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell stem cell. 2008;3(6): 637-48.
102. Marchetto MC, Muotri AR, Mu Y, Smith AM, Cezar GG, Gage FH. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008;3(6): 649-57.
103. Koizumi S, Fujishita K, Inoue K. Regulation of cell-to-cell communication mediated by astrocytic ATP in the CNS. Purinergic Signal. 2005;1(3): 211-7.
104. Fellin T, Sul JY, D'Ascenzo M, Takano H, Pascual O, Haydon PG. Bidirectional astrocyte-neuron communication: the many roles of glutamate and ATP. Novartis Found Symp. 2006;276: 208-17; discussion 17-21, 33-7, 75-81.
105. Yang C, Wang H, Qiao T, Yang B, Aliaga L, Qiu L, et al., Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2014;111(12): E1121-9.
106. Rojas F, Cortes N, Abarzua S, Dyrda A, van Zundert B. Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Front Cell Neurosci. 2014;8: 24.
107. Casula M, Iyer AM, Spliet WG, Anink JJ, Steentjes K, Sta M, et al., Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience. 2011;179: 233-43.
108. Okun E, Griffioen KJ, Son TG, Lee JH, Roberts NJ, Mughal MR, et al., TLR2 activation inhibits embryonic neural progenitor cell proliferation. J Neurochem. 2010;114(2): 462-74.
109. Freria CM, Velloso LA, Oliveira AL. Opposing effects of Toll-like receptors 2 and 4 on synaptic stability in the spinal cord after peripheral nerve injury. J Neuroinflammation. 2012;9: 240.
110. Cui Y, Masaki K, Yamasaki R, Imamura S, Suzuki SO, Hayashi S, et al., Extensive dysregulations of oligodendrocytic and astrocytic connexinsare associated with disease progression in an amyotrophic lateral sclerosis mouse model. J Neuroinflammation. 2014;11: 42.
111. Sun H, Liang R, Yang B, Zhou Y, Liu M, Fang F, et al., Aquaporin-4 mediates communication between astrocyte and microglia: Implications of neuroinflammation in experimental Parkinson's disease. Neuroscience. 2016;317: 65-75.
112. Strohschein S, Huttmann K, Gabriel S, Binder DK, Heinemann U, Steinhauser C. Impact of aquaporin-4 channels on K+ buffering and gap junction coupling in the hippocampus. Glia. 2011;59(6): 973-80.
113. Takeuchi H, Suzumura A. Gap junctions and hemichannels composed of connexins: potential therapeutic targets for neurodegenerative diseases. Front Cell Neurosci. 2014;8: 189.
114. Nakase T, Naus CC. Gap junctions and neurological disorders of the central nervous system. Biochim Biophys Acta. 2004;1662(1-2): 149-58.
115. Lutz SE, Zhao Y, Gulinello M, Lee SC, Raine CS, Brosnan CF. Deletion of astrocyte connexins 43 and 30 leads to a dysmyelinating phenotype and hippocampal CA1 vacuolation. J Neurosci. 2009;29(24): 7743-52.
116. Retamal MA, Froger N, Palacios-Prado N, Ezan P, Saez PJ, Saez JC, et al., Cx43 hemichannels and gap junction channels in astrocytes are regulated oppositely by proinflammatory cytokines released from activated microglia. J Neurosci. 2007;27(50): 13781-92.
117. Valori CF, Brambilla L, Martorana F, Rossi D. The multifaceted role of glial cells in amyotrophic lateral sclerosis. Cell Mol Life Sci. 2014;71(2): 287-97.
118. Staats KA, Van Den Bosch L. Astrocytes in amyotrophic lateral sclerosis: direct effects on motor neuron survival. J Biol Phys. 2009;35(4): 337-46.
119. Ferraiuolo L, Higginbottom A, Heath PR, Barber S, Greenald D, Kirby J, et al., Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain. 2011;134(Pt 9): 2627-41.
120. Sasabe J, Chiba T, Yamada M, Okamoto K, Nishimoto I, Matsuoka M, et al., D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. EMBO J. 2007;26(18): 4149-59.
121. Sasabe J, Miyoshi Y, Suzuki M, Mita M, Konno R, Matsuoka M, et al., D-amino acid oxidase controls motoneuron degeneration through Dserine. Proc Natl Acad Sci U S A. 2012;109(2): 627-32.
122. Aronica E, Catania MV, Geurts J, Yankaya B, Troost D. Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes. Neuroscience. 2001;105(2): 509-20.
123. Seifert G, Schilling K, Steinhauser C. Astrocyte dysfunction in neurological disorders: a molecular perspective. Nat Rev Neurosci. 2006;7(3): 194-206.
124. Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2004;88(3): 576-82.
125. Drachman DB, Frank K, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, et al., Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2002;52(6): 771-8.
126. Pompl PN, Ho L, Bianchi M, McManus T, Qin W, Pasinetti GM. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2003;17(6): 725-7.
127. Pehar M, Cassina P, Vargas MR, Castellanos R, Viera L, Beckman JS, et al., Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem. 2004;89(2): 464-73.
128. Kawamata H, Ng SK, Diaz N, Burstein S, Morel L, Osgood A, et al., Abnormal intracellular calcium signaling and SNARE-dependent exocytosis contributes to SOD1G93A astrocyte-mediated toxicity in amyotrophic lateral sclerosis. J Neurosci. 2014;34(6): 2331-48.
129. Aryani A, Denecke B. Exosomes as a Nanodelivery System: a Key to the Future of Neuromedicine? Mol Neurobiol. 2016;53(2): 818-34.
130. Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet. 2012;21(R1): R125-34.
131. Feng D, Zhao WL, Ye YY, Bai XC, Liu RQ, Chang LF, et al., Cellular internalization of exosomes occurs through phagocytosis. Traffic. 2010;11(5): 675-87.
132. Chen TS, Lai RC, Lee MM, Choo AB, Lee CN, Lim SK. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res. 2010;38(1): 215-24.
133. Alexander M, Hu R, Runtsch MC, Kagele DA, Mosbruger TL, Tolmachova T, et al., Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun. 2015;6: 7321.
134. Falchi AM, Sogos V, Saba F, Piras M, Congiu T, Piludu M. Astrocytes shed large membrane vesicles that contain mitochondria, lipid droplets and ATP. Histochem Cell Biol. 2013;139(2): 221-31.
135. Gomes C, Keller S, Altevogt P, Costa J. Evidence for secretion of Cu, Zn superoxide dismutase via exosomes from a cell model of amyotrophic lateral sclerosis. Neurosci Lett. 2007;428(1): 43-6.
136. Silverman JM, Fernando SM, Grad LI, Hill AF, Turner BJ, Yerbury JJ, et al., Disease Mechanisms in ALS: Misfolded SOD1 Transferred Through Exosome-Dependent and Exosome-Independent Pathways. Cell Mol Neurobiol. 2016;36(3): 377-81.
137. Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles. 2014;3.
138. Schneider A, Simons M. Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res. 2013;352(1): 33-47.
139. Morel L, Regan M, Higashimori H, Ng SK, Esau C, Vidensky S, et al., Neuronal exosomal miRNA-dependent translational regulation of astroglial glutamate transporter GLT1. J Biol Chem. 2013;288(10): 7105-16.
140. Grad LI, Pokrishevsky E, Silverman JM, Cashman NR. Exosomedependent and independent mechanisms are involved in prion-like transmission of propagated Cu/Zn superoxide dismutase misfolding. Prion. 2014;8(5): 331-5.
141. Gosselin RD, Meylan P, Decosterd I. Extracellular microvesicles from astrocytes contain functional glutamate transporters: regulation by protein kinase C and cell activation. Front Cell Neurosci. 2013;7: 251.
142. Lasiene J, Yamanaka K. Glial cells in amyotrophic lateral sclerosis. Neurol Res Int. 2011;2011: 718987.
143. Kruminis-Kaszkiel E, Wojtkiewicz J, Maksymowicz W. Glial-restricted precursors as potential candidates for ALS cell-replacement therapy. Acta Neurobiol Exp (Wars). 2014;74(3): 233-41.
144. Feldman EL, Boulis NM, Hur J, Johe K, Rutkove SB, Federici T, et al., Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol. 2014;75(3): 363-73.
145. Lopez-Gonzalez R, Kunckles P, Velasco I. Transient recovery in a rat model of familial amyotrophic lateral sclerosis after transplantation of motor neurons derived from mouse embryonic stem cells. Cell Transplant. 2009;18(10): 1171-81.
146. Thonhoff JR, Ojeda L, Wu P. Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis. Curr Stem Cell Res Ther. 2009;4(3): 178-99.
147. Teng YD, Benn SC, Kalkanis SN, Shefner JM, Onario RC, Cheng B, et al., Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis. Sci Transl Med. 2012;4(165): 165ra4.
148. Xu L, Yan J, Chen D, Welsh AM, Hazel T, Johe K, et al., Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation. 2006;82(7): 865-75.
149. Yan J, Xu L, Welsh AM, Chen D, Hazel T, Johe K, et al., Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice. Stem Cells. 2006;24(8): 1976-85.
150. Ferraiuolo L, Frakes A, Kaspar BK. Neural stem cells as a therapeutic approach for amyotrophic lateral sclerosis. Mol Ther. 2013;21(3): 503-5.
151. Riley J, Glass J, Feldman EL, Polak M, Bordeau J, Federici T, et al., Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes. Neurosurgery. 2014;74(1): 77-87.
152. Mazzini L, Gelati M, Profico DC, Sgaravizzi G, Projetti Pensi M, Muzi G, et al., Human neural stem cell transplantation in ALS: initial results from a phase I trial. J Transl Med. 2015;13: 17.
153. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al., Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433(7021): 73-7.
154. Ratti E, Berry JD, Greenblatt DJ, Loci L, Ellrodt AS, Shefner JM, et al., Preclinical Rodent Toxicity Studies for Long Term Use of Ceftriaxone. Toxicology reports. 2015;2: 1396-403.
155. Raheja D, Stephens HE, Lehman E, Walsh S, Yang C, Simmons Z. Patient-reported problematic symptoms in an ALS treatment trial. Amyotrophic lateral sclerosis & frontotemporal degeneration. 2016: 1-8.
156. Boucherie C, Schafer S, Lavand'homme P, Maloteaux JM, Hermans E. Chimerization of astroglial population in the lumbar spinal cord after mesenchymal stem cell transplantation prolongs survival in a rat model of amyotrophic lateral sclerosis. J Neurosci Res. 2009;87(9): 2034-46.
157. Knippenberg S, Thau N, Dengler R, Brinker T, Petri S. Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS. PLoS One. 2012;7(6): e36857.
158. Lunn JS, Sakowski SA, Feldman EL. Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future. Stem cells. 2014;32(5): 1099-109.
159. Suzuki M, McHugh J, Tork C, Shelley B, Klein SM, Aebischer P, et al., GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One. 2007;2(8): e689.
160. Dadon-Nachum M, Ben-Yaacov K, Ben-Zur T, Barhum Y, Yaffe D, Perlson E, et al., Transplanted modified muscle progenitor cells expressing a mixture of neurotrophic factors delay disease onset and enhance survival in the SOD1 mouse model of ALS. J Mol Neurosci. 2015;55(3): 788-97.
161. Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, et al., Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. JAMA neurology. 2016;73(3): 337-44.
162. Haidet-Phillips AM, Doreswamy A, Gross SK, Tang X, Campanelli JT, Maragakis NJ. Human glial progenitor engraftment and gene expression is independent of the ALS environment. Exp Neurol. 2015;264: 188-99.
163. Roybon L, Lamas NJ, Garcia-Diaz A, Yang EJ, Sattler R, Jackson-Lewis V, et al., Human stem cell-derived spinal cord astrocytes with defined mature or reactive phenotypes. Cell Rep. 2013;4(5): 1035-48.
164. Chen H, Qian K, Chen W, Hu B, Blackbourn LWt, Du Z, et al., Humanderived neural progenitors functionally replace astrocytes in adult mice. J Clin Invest. 2015;125(3): 1033-42.
165. Villarroya-Beltri C, Gutierrez-Vazquez C, Sanchez-Cabo F, Perez-Hernandez D, Vazquez J, Martin-Cofreces N, et al., Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun. 2013;4: 2980.
166. Jung HJ, Suh Y. MicroRNA in Aging: From Discovery to Biology. Curr Genomics. 2012;13(7): 548-57.
167. Weilner S, Schraml E, Redl H, Grillari-Voglauer R, Grillari J. Secretion of microvesicular miRNAs in cellular and organismal aging. Exp Gerontol. 2013;48(7): 626-33.
168. Braccioli L, van Velthoven C, Heijnen CJ. Exosomes: a new weapon to treat the central nervous system. Mol Neurobiol. 2014;49(1): 113-9.
169. Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, et al., Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013;21(1): 185-91.
170. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4): 341-5.
171. Momen-Heravi F, Bala S, Bukong T, Szabo G. Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. Nanomedicine. 2014;10(7): 1517-27.
172. de Rivero Vaccari JP, Brand F, 3rd, Adamczak S, Lee SW, Perez-Barcena J, Wang MY, et al., Exosome-mediated inflammasome signaling after central nervous system injury. J Neurochem. 2016;136 Suppl 1: 39-48.
173. Lener T, Gimona M, Aigner L, Borger V, Buzas E, Camussi G, et al., Applying extracellular vesicles based therapeutics in clinical trials-an ISEV position paper. J Extracell Vesicles. 2015;4: 30087.
174. Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D'Avanzo C, et al., A three-dimensional human neural cell culture model of Alzheimer's disease. Nature. 2014;515(7526): 274-8.
175. Carlson AL, Bennett NK, Francis NL, Halikere A, Clarke S, Moore JC, et al., Generation and transplantation of reprogrammed human neurons in the brain using 3D microtopographic scaffolds. Nat Commun. 2016;7: 10862.
176. Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;364(6435): 362.
177. Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin M, et al., Novel antibodies reveal inclusions containing nonnative SOD1 in sporadic ALS patients. PLoS One. 2010;5(7): e11552.
178. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314 (5796): 130-3.
179. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al., TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870): 1668-72.
180. Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al., Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61(5): 427-34.
181. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al., Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918): 1208-11.
182. Zou ZY, Cui LY, Sun Q, Li XG, Liu MS, Xu Y, et al., De novo FUS gene mutations are associated with juvenile-onset sporadic amyotrophic lateral sclerosis in China. Neurobiol Aging. 2013;34(4): 1312 e1-8.
183. Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, et al., ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet. 2006;38(4): 411-3.
184. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al., Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465(7295): 223-6.
185. van Blitterswijk M, van Vught PW, van Es MA, Schelhaas HJ, van der Kooi AJ, de Visser M, et al., Novel optineurin mutations in sporadic amyotrophic lateral sclerosis patients. Neurobiol Aging. 2011;33(5): 1016 e1-7.
186. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2): 257-68.
187. Lattante S, Conte A, Zollino M, Luigetti M, Del Grande A, Marangi G, et al., Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease. Neurology. 2012;79(1): 66-72.